Avacopan for the Treatment of ANCA-Associated Vasculitis | NEJM
The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis. In this randomized, controlled trial, we assigned patient…